They are funded through until at least mid next year by which time they will have results of three phase 2 trials. The most important milestone this year is the interim data release for SNT 5505 in myelofibrosis - and a presentation at ASH in December. Spec buy and hold until then in my opinion.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
6.0¢ |
Change
-0.003(4.76%) |
Mkt cap ! $97.55M | |||
| Open | High | Low | Value | Volume |
| 6.3¢ | 6.6¢ | 6.0¢ | $154.2K | 2.423M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 273330 | 6.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.2¢ | 150000 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| SNT (ASX) Chart |